Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo. As Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed […]

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 25 Sep 2015

This week’s major stories outside the EU you NEED to read! (Martin Shkreli, Biolimb, OrbiMed)

Happy Saturday everyone! This week was full of so many good articles, we’re doing a top 7 top stories outside the EU you need to know! Yes, you heard correctly, seven of the best articles for your reading pleasure, you are most welcome ;). THE CEO WHO JACKED UP THE PRICE OF A DRUG BY 5000% […]

September 25, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 25 Sep 2015

Two French Biotechs are fighting in court…for nothing

We are all familiar with stories of lawsuits in the tech sector (e.g. remember the Apple and Samsung debacle?) but it’s less well known for Biotechs to butt heads. Nonetheless, the French-Danish Biotech oncology company Onxeo, and Eurofins (a huge 19K employee group which deals in clinical services) fought it out in Paris’ commerce court: to […]

September 25, 2015 - 3 minutesmins - By Philip Hemme

Inside Labiotech 23 Sep 2015

Labiotech.eu is 1 year old: Discover our Entrepreneurial Journey!

Hi there, Yesterday, with 30 guests from Berlin, we celebrated the first year of Labiotech.eu! Not only that we survived but we also have now more than 15,000 people visiting our website each month. Thank you all, that makes us the Europe’s leading digital media for Biotech! I am extremely proud of what we achieved and […]

September 23, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn’t changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech startups worldwide) has just published positive phase III results of its implantable device aiming at changing how type 2 diabetes are treated. November 2014: I thought […]

September 18, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

Gene Editing has been made much easier thanks to CRISPR but managing your genome editing workflow can be a challenge. London-based Desktop Genetics wants to solve this problem and just raised additional funding to accelerate its development. CRISPR is already considered as the biotech revolution of this century. Having an easy tool is one thing, but being […]

September 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Sep 2015

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it … Talking about billon-dollar companies in the US is such a hype. Even the Wall street journal has its own start-up club (which btw is stunning). By looking at it, I wondered which European Biotechs were worth over €1Bn in Europe. […]

September 15, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 12 Sep 2015

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Oh hey there…another Top 5 topics you need to know from outside Europe this week. Hope you enjoy and if you have time, give us some feedback! FOUNDER OF THERANOS: MODERN DIAGNOSIS OF DISEASE IS TOO LATE “If you look up the word ‘diagnose’ in the dictionary, it’ll say ‘to determine the presence of disease from […]

September 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Sep 2015

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

This is the story of how Abcam and Horizon fell in collaborative-biotech-love and finally came together to partner up on antibody research. Whilst doing his post-doc at University of Cambridge, Jonathan Milner had an idea to improve how antibodies could be produced for researchers around the World. Thus, he founded the company Abcam in 1998. Over […]

September 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Sep 2015

The First Biosimilar reached the US market… and it’s from Novartis

Biosimilar or copies of biological drugs are arriving on the market. After Europe, US gets its first Biosimilar too. The drug is produced by Novartis generic subsidiary, Sandoz and it will compete with Amgen‘s blockbuster drug Neupogen. When a drug generates $1.2Bn of annual revenues and its patent has expired, which company on earth wouldn’t be […]

September 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 5 Sep 2015

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Genzyme’s $22.28M (€20M) penalty wasn’t enough for the US Department of Justice to resolve its criminal marketing of Seprafilm. Sanofi’s biotech subsidiary will therefore have to pay another $32.5M (€29,2M) to avoid further legal implications. Criminal charges caught Cambridge-based Genzyme by promoting its tape-like Seprafilm for wrong allegations between 2005 and 2010, up until one year […]

September 5, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

Will Roche lose its Worldwide Leading position in Cancer treatments?

This week’s major stories outside the EU you NEED to read! (Martin Shkreli, Biolimb, OrbiMed)

Two French Biotechs are fighting in court…for nothing

Labiotech.eu is 1 year old: Discover our Entrepreneurial Journey!

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

The First Biosimilar reached the US market… and it’s from Novartis

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!